Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advair: A Big Generic Opportunity And A Big Question Mark In 2017

Executive Summary

Takeda’s Velcade, Pfizer’s Viagra and Gilead’s Viread are among the brand drugs expected to face generic competition in the US for the first time in 2017. One unknown is if FDA will approve Mylan’s or Hikma’s ANDAs for a generic version of GSK’s Advair.

You may also be interested in...



Mylan Plans Summer Launch For Advair Generic, Now Called Wixela Inhub

Wixela Inhub could be the first interchangeable generic version of the blockbuster asthma drug on the US market if it is approved by FDA.

Mylan Plans Summer Launch For Advair Generic, Now Called Wixela Inhub

Wixela Inhub could be the first interchangeable generic version of the blockbuster asthma drug on the US market if it is approved by FDA.

GSK Braces For Impact: Advair Generic Could Reduce US Brand To £1Bn

Although it’s not yet clear if an interchangeable version of the respiratory blockbuster will be approved by FDA, CEO Andrew Witty prepared investors to expect a hit, forecasting that a mid-year launch could significantly reduce revenues.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM004514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel